HomeCompareCLHLF vs ABBV

CLHLF vs ABBV: Dividend Comparison 2026

CLHLF yields 5.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLHLF wins by $9.15M in total portfolio value· pulled ahead in Year 2
10 years
CLHLF
CLHLF
● Live price
5.09%
Share price
$61.16
Annual div
$3.12
5Y div CAGR
65.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.25M
Annual income
$7,413,102.32
Full CLHLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CLHLF vs ABBV

📍 CLHLF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLHLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLHLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLHLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLHLF
Annual income on $10K today (after 15% tax)
$433.04/yr
After 10yr DRIP, annual income (after tax)
$6,301,136.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CLHLF beats the other by $6,280,080.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLHLF + ABBV for your $10,000?

CLHLF: 50%ABBV: 50%
100% ABBV50/50100% CLHLF
Portfolio after 10yr
$4.67M
Annual income
$3,718,937.04/yr
Blended yield
79.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CLHLF
No analyst data
Altman Z
8.0
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLHLF buys
0
ABBV buys
0
No recent congressional trades found for CLHLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLHLFABBV
Forward yield5.09%3.06%
Annual dividend / share$3.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR65.7%40.6%
Portfolio after 10y$9.25M$102.3K
Annual income after 10y$7,413,102.32$24,771.77
Total dividends collected$9.06M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CLHLF vs ABBV ($10,000, DRIP)

YearCLHLF PortfolioCLHLF Income/yrABBV PortfolioABBV Income/yrGap
1$11,544$844.17$11,550$430.00$6.00ABBV
2← crossover$13,861$1,509.15$13,472$627.96+$389.00CLHLF
3$17,638$2,806.19$15,906$926.08+$1.7KCLHLF
4$24,402$5,529.61$19,071$1,382.55+$5.3KCLHLF
5$37,958$11,847.18$23,302$2,095.81+$14.7KCLHLF
6$69,152$28,537.96$29,150$3,237.93+$40.0KCLHLF
7$154,507$80,514.06$37,536$5,121.41+$117.0KCLHLF
8$443,904$278,580.98$50,079$8,338.38+$393.8KCLHLF
9$1,714,430$1,239,453.37$69,753$14,065.80+$1.64MCLHLF
10$9,247,543$7,413,102.32$102,337$24,771.77+$9.15MCLHLF

CLHLF vs ABBV: Complete Analysis 2026

CLHLFStock

COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. It offers restoration products, including conventional composites, bulk-fill composites, CAD/CAM solutions, core build-ups, bondings, etching gels, temporary materials, luting, curing lights, and characterizations; and endodontics products, such as posts, rotary and hand files, irrigation solutions, obturation and sealing materials, Gutta-percha and paper points, endo engines, apex locators, and endo accessories. The company also provides prosthetics comprising bite registration, retractions, A-silicones, C-silicones, and accessories; and treatment auxiliaries consisting of dental rolls and dispensers, cotton pellets and dispensers, aspirator tips, dental dams and dam kits, dental dam clamps and accessories, dental scalers, electrosurgery, and occlusion verification products. In addition, it offers infection control products, which include ultrasonic cleaning units, patient bibs, headrest covers, and sterile covers; rotary instruments, such as diamond and carbide burs, polishers, kits, and accessories; and laboratory products comprising gingiva masks, lab putty products, model making products, waxes, occlusion control products, accessories, HP burs, and silicone polishers. The company was formerly known as Medisize Holding AG and changed its name to COLTENE Holding AG in April 2008. COLTENE Holding AG was incorporated in 2005 and is headquartered in Altstätten, Switzerland.

Full CLHLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CLHLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLHLF vs SCHDCLHLF vs JEPICLHLF vs OCLHLF vs KOCLHLF vs MAINCLHLF vs JNJCLHLF vs MRKCLHLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.